With today’s news that Medicare will cover Signatera for stage I-III non-small cell lung cancer in surveillance, Signatera is now more accessible to patients living with lung cancer – the most lethal and one of the most common forms of cancer in the United States. Signatera test performance and utility in the surveillance setting for stage I-III NSCLC was validated in three independent peer-reviewed studies to support this coverage determination. The body of evidence continues to grow demonstrating Signatera’s value across a broad range of cancer indications and settings. Read more in our latest press release. https://ow.ly/44Jf50V65LQ
Natera
生物技术研究
Austin，Texas 167,601 位关注者
We are a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health.
关于我们
Natera? is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. Our aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier and more targeted interventions that lead to longer, healthier lives. Where some set out to build?a test, we set out to achieve a mission: change the management of disease worldwide by using DNA testing to proactively inform treatment.? Through a cfDNA technology platform approach, we've pioneered noninvasive testing in unlimited applications—each with their own potential to revolutionize care for patients. #TeamNatera includes clinicians, scientists, biostatisticians, researchers, and laboratory professionals from around the world. Our diverse teams blend a passion for patients with deep clinical, scientific, and technological roots. Natera’s tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Interested in joining us on our mission to?change the management of disease worldwide? Visit?https://www.natera.com/careers-at-natera to learn how you can become a part of our talented team. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. Please be advised that Natera will reach out to candidates with an @natera.com email domain ONLY. Email communications from all other domain names are not from Natera or its employees and are fraudulent. Natera does not request interviews via text messages and does not ask for personal information until a candidate has engaged with the company and has spoken to a recruiter and the hiring team. Natera takes cyber crimes seriously, and will collaborate with law enforcement authorities to prosecute any related cyber crimes. https://www.natera.com/privacy/
- 网站
-
https://www.natera.com
Natera的外部链接
- 所属行业
- 生物技术研究
- 规模
- 1,001-5,000 人
- 总部
- Austin，Texas
- 类型
- 上市公司
- 创立
- 2004
- 领域
- Non-Invasive Prenatal Testing (NIPT)、Single gene diseases、Preimplantation Genetic Screening (PGS)/Diagnosis (PGD)、Biopsy training、Multi-Disease Carrier Screening、Bioinformatics、Miscarriage testing、Genetic counseling、Non-invasive paternity testing、Genetics、colorectal cancer、Oncology、Transplant、Kidney Transplant、Cancer、Transplant Rejection和ctDNA
地点
Natera员工
动态
-
Congratulations to Chitra Kotwaliwale, Ph.D., SVP of Clinical & Commercial Operations at Natera, for being named one of the Top 50 Women Leaders in Healthcare Technology by The Healthcare Technology Report! This recognition is a testament to her enduring impact and leadership. ?? https://ow.ly/T3Fy50UXH5i
-
We’re pleased to share that the National Comprehensive Cancer Network? (NCCN?) strengthened its guidance on circulating tumor DNA (ctDNA) testing in colon cancer, rectal cancer, and merkel cell carcinoma (MCC). These are significant milestones for MRD testing and Signatera, as we work to improve the management of patients with cancer. For colon and rectal cancer, NCCN now includes ctDNA as a high-risk factor for recurrence in the adjuvant setting, recognizing its prognostic value. This represents an important step forward as the first time the guidelines have formally recognized the value of ctDNA as a prognostic biomarker. In MCC, the guideline now includes a positive recommendation for ctDNA monitoring in surveillance and cites Signatera data published in 2024 in the Journal of Clinical Oncology. We are hopeful these are the first of many major updates to NCCN guidelines re: ctDNA for MRD assessment, underscoring the important role Signatera has in helping patients with cancer. https://ow.ly/Q83850UX9bZ #Signatera #Natera #ctDNA #Merkel
NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma
natera.com
-
Congratulations to our executive chairman and co-founder Matthew Rabinowitz, PhD, who was celebrated yesterday as a Luminary Honoree at the PMWC - Precision Medicine World Conference. In accepting his award, Matt delivered a keynote presentation to a packed room entitled "The Power of a Blood Sample: Predictive Diagnostics and Transforming Healthcare." Premal Shah, Ph.D. of MyOme, another company Matt co-founded, gave a poignant introduction of Matt and his impact on patients across different segments of healthcare. ? Matt has been a longtime champion of innovation. His vision and leadership have led Natera to become a driving force in healthcare today, creating several new categories with transformational products across oncology, women’s health and organ health. #PrecisionMedicine #PMWC25 #Natera
-
-
Natera in bright lights on the big screen! On 2/4/25, Nasdaq ran this display in Times Square during market hours to congratulate CEO Steve Chapman and Natera. This is a testament to Steve's leadership as CEO and Natera's impact on patient care. Later this year, we will celebrate our 10-year anniversary as a publicly traded company. #Nasdaq #Natera The Healthcare Technology Report BioTech Breakthrough
-
-
We are looking forward to the 24th PMWC - Precision Medicine World Conference (#PMWC25) this week. Congratulations to our co-founder and executive chairman Matthew Rabinowitz, PhD on being recognized as a PMWC Luminary Honoree! Don’t miss Matt’s keynote, "The Power of a Blood Sample: Predictive Diagnostics and Transforming Healthcare" on Feb. 6 at 4:30 PM PT. https://ow.ly/TEy850USp7q
-
-
Natera转发了
A major highlight from Natera at ASCO GI: new trial data showcasing how Signatera has the potential to transform disease management for colorectal cancer patients, one of the deadliest cancers in the world. In the analysis that was performed, Signatera helped to identify patients who may benefit from an escalation in adjuvant therapy, with MRD-positive patients showing a significant improvement in survival rates when combining an NSAID with standard of care therapy.? This data has the potential to be a game-changer in how we approach colorectal cancer treatment, paving the way for more targeted, effective care. Huge kudos to the Natera team for their continued innovation in advancing cancer care.
Clinical evidence on #Signatera continues to strengthen with the latest data presented at ASCO GI this past weekend. Of the many highlights, the 80702 trial demonstrated that Signatera-positive patients who were treated with both adjuvant chemotherapy and celecoxib had a 40% improvement in overall survival versus chemotherapy alone. These data offer compelling evidence to address an unmet need in adjuvant colorectal cancer treatment, where there has not been a new drug approval in over 20 years. https://ow.ly/AiX150UNTUV #GI25
-